Physician profile
Nathan Singer
NPI 1114108016
$2,192.36
in general payments reported to CMS, 2019-2025
10 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $60.29 · 2021: $317 · 2022: $961 · 2023: $234 · 2024: $171 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,067.46 | 2019-2025 | Proclaim |
| Abbvie INC. | $251.40 | 2022-2023 | Qulipta, Ubrelvy |
| Boston Scientific Corporation | $230.55 | 2020-2025 | General - Pain Management |
| Grt US Holding, INC. | $189.00 | 2022 | |
| Nevro Corp. | $135.71 | 2021 | |
| Amgen INC. | $102.07 | 2019 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $73.31 | 2024 | Sprint Pns System |
| Painteq LLC | $26.63 | 2023 | Painteq |
| Virtus Pharmaceuticals LLC | $18.28 | 2025 | Levorphanol Tartrate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.